Saad Z. Usmani, MD, MBA, FACP, FASCO

Phase 1 data show oral NSD2 inhibitor KTX-1001 delivers durable disease control in high-risk myeloma, with manageable thrombocytopenia and combo plans.

KTX-1001, a novel oral inhibitor of NSD2, demonstrates early clinical activity and manageable safety in heavily pretreated multiple myeloma.

Multidisciplinary approaches are crucial in treating complex cancer patients, focusing on tailored therapies and symptom management strategies.

Saad Usmani, MD, MBA, FACP, FASCO, explores treatment duration, patient characteristics, and toxicity profiles in transplant-ineligible patients with newly diagnosed multiple myeloma.

Saad Usmani, MD, MBA, FACP, FASCO, discusses the subgroup analysis of transplant-ineligible patients with newly diagnosed multiple myeloma from the CEPHEUS trial.